Rein Therapeutics

Contributing Author

Recent Articles by Rein Therapeutics

Apr-30	Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock RNTX -23.99% GlobeNewswire
Apr-29	Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX -12.07% GlobeNewswire
Mar-03	Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Jan-20	Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Nov-06	Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF RNTX GlobeNewswire
Nov-03	Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX +11.82% GlobeNewswire
Oct-09	Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Sep-17	Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Aug-19	Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis RNTX GlobeNewswire
Aug-14	Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 RNTX GlobeNewswire
Jul-30	Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing RNTX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)